ArticleJournal of cancer research and clinical oncology2020

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

Hisao Imai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.